Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Phase I Evaluation of MaaT033, a Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule, In HeMatOlogy Malignant Patients Under iNtensive Chemotherapy (CIMON)

NCT04150393 is registered in ClinicalTrials.gov with MaaT Pharma as lead sponsor.

NCT NCT04150393
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04150393 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Phase I Evaluation of MaaT033, a Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule, In HeMatOlogy Malignant Patients Under iNtensive Chemotherapy (CIMON)
Lead sponsor
MaaT Pharma
Phase
Phase 1
Overall status
Completed
Start date
October 20, 2020
Completion date
December 13, 2021
Enrollment
21 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy effect, hematologic diseases